Panelist discusses how genetic testing is recommended for all patients with pancreatic adenocarcinoma at diagnosis, including ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Panelist discusses how pancreatic adenocarcinoma remains one of the deadliest cancers with poor survival rates, presenting a case of a 58-year-old patient with locally advanced disease and reviewing ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

A phase 3 study shows Cylembio combined with pembrolizumab improves progression-free survival in advanced melanoma, ...

New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic ...

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal ...

The CAR-T treatment GLPG5101 received the FDA's RMAT designation by showing promising efficacy with rapid delivery and low toxicity in mantle cell lymphoma.

Marwan G. Fakih, MD, discusses barriers that create treatment differences in metastatic colorectal cancer for community oncologists.

A phase 1/2 trial reveals sacituzumab tirumotecan shows manageable toxicity and promising antitumor activity in patients with ...

During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

Enzalutamide's efficacy is supported by preference studies and a MAIC, helping doctors and patients make informed treatment ...